Curzest for DiabetesEffective management of diabetes with Curzest
Diabetes can result in various vascular complications such as neuropathy, nephropathy, retinopathy, and cardiomyopathy, which are major sources of morbidity and mortality associated with diabetes. Most of the patients even with well controlled diabetes shall develop these complication with increased duration of disease.
The key pathogenic events underlying the hyperglycemia-associated vascular complications include oxidative stress, inflammation, and associated pathophysiologic pathways. Oxidative stress- induced activation of various cellular pathways and resultant inflammatory episodes contributes to the endothelial damage in the blood capillaries of organs such as the retina, peripheral neurons, and kidneys leading to retinopathy, neuropathy, and nephropathy, respectively.
Unfortunately we don’t have any effective treatment once these complications develop. Prevention of these complications is of utmost importance. However, for prevention we need something that has been shown to be efficacious with no side effects.
Curcumin because of the various actions as detailed in the figure is able to effectively prevent development of microangiopathy and hence development of these complications. In some studies, it has been shown to be effective even in patients who have developed these complications.
Curzest modulates multiple cell signalling molecules
- Prostaglandin E2
- Glutathione (GSH)
- Pepsinogen, phosphorylase kinase (PhK)
- Transferrin receptor, total cholesterol, transforming growth factor (TGF)-β
- HO-1, antioxidants
- Pro-inflammatory cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-1β, IL-6)
- Apoptotic proteins, NF–κB
- Cyclooxygenase (COX)-2,\STAT3, IKKβ
- Malondialdehyde (MDA)
- C reactive protein (CRP)
References / Research
Curcumin and Diabetes – a systematic review
Curcumin has caught attention as a potential treatment for diabetes and its complications primarily because it is a relatively safe and inexpensive drug that reduces glycemia and hyperlipidemia in rodent models of diabetes…
Zhang DW(1), Fu M(2), Gao SH(1), Liu JL(2) Evid Based Complement Alternat Med. 2013;2013:636053
Curcumin: a pleiotropic phytonutrient
The pleiotropic regulation of redox balance of cell and inflammation might be the basis of curcumin’s beneficial activities in various pathologic conditions including diabetic complications…
Jeenger MK(1), Shrivastava S(1), Yerra VG(1), Naidu VG(1), Ramakrishna S(2), Kumar A(3). Nutrition. 2015 Feb;31(2):276-82.
Diabetic nephropathy by suppressing TGF-β
Short-term supplementation can attenuate proteinuria, TGF-β and IL-8 in patients with overt type 2 diabetic nephropathy and can be administered as a safe adjuvant therapy for these patients…
Read more Khajehdehi P(1), Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, Dehghanzadeh G. Scand J Urol Nephrol. 2011 Nov;45(5):365-70
Molecular understanding of curcumin in diabetic nephropathy
Diabetic nephropathy is characterized by a plethora of signaling abnormalities. The renoprotective role of curcumin in diabetes mellitus (DM) is highlighted with an emphasis on the molecular basis of this effect…
Soetikno V(1), Suzuki K, Veeraveedu PT, Arumugam S, Lakshmanan AP, Sone H, Watanabe K.
Antinociceptive effect of Curcumin
Curcumin ameliorated diabetic neuropathy partially by inhibition of NADPH oxidase mediating oxidative stress in the spinal cord. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases are the main enzymes that produce oxidative stress…
Neurosci Lett. 2014 Feb 7;560:81-5. Zhao WC(1), Zhang B(1), Liao MJ(1), Zhang WX(1), He WY(1), Wang HB(1), Yang CX(2)
Therapeutic implications of curcumin in the prevention of diabetic retinopathy
Curcumin has been observed to have therapeutic potential in the inhibition or in slowing down progression of Diabetic Retinopathy (DR). DR is one of the most common complications of diabetes mellitus that affects the blood vessels of the retina, leading to blindness…
Read more Aldebasi YH(1), Aly SM(2), Rahmani AH(3). Int J Physiol Pathophysiol Pharmacol. 2013 Dec 15;5(4):194-202